35
Health
28 February 2024, 12:55 pm 1 minute
Reuters exclusively reported that U.S. drugmaker Eli Lilly LLY.N expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review.
Market Impact
The market opportunity is huge in the world’s most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally.
Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: Asia
Countries: India
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Significant National Story
